PRA Health Sciences
 |
|
| PRA Health Sciences Inc. | |
|
Formerly called
|
PRA International |
| Public | |
| Traded as | NASDAQ: PRAH |
| Industry | Pharmaceuticals & Biotechnology |
| Founded | Charlottesville, Virginia, United States (1976) |
| Headquarters | Raleigh, North Carolina, United States |
|
Number of locations
|
80+ countries |
|
Area served
|
Worldwide |
|
Key people
|
Colin Shannon (President and CEO) |
|
Number of employees
|
~13,000 |
| Website | prahs |
PRA Health Sciences is a contract research organization with headquarters in Raleigh, North Carolina, USA. The organization has worked on 100+ drugs marketed across several therapeutic areas and conducted the pivotal or supportive trials that led to U.S. Food and Drug Administration (FDA) and/or international regulatory approval of 50+ such drugs.
PRA was founded in 1976 as the Anti-Inflammatory Drug Study Group in Charlottesville, Virginia, USA. Renamed PRA in 1982, it established itself as a data-management Contract Research Organization (CRO). After a number of strategic decisions to enhance its service offerings, the company became PRA Health Sciences in June 2014, incorporating partnerships and acquisitions made throughout 2012 and 2013.
Key dates:
PRA Health Sciences (PRA) has worked to develop a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.
PRA has participated in several Clinical Trials of note such as the Landmark Alzheimer's Prevention Clinical Trial, a collaborative effort involving the Banner Alzheimer's Institute (BAI); Genentech, a member of the Roche Group; the University of Antioquia in Colombia; and the National Institutes of Health (NIH).
PRA were instrumental in supporting Gilead Sciences, Inc. with an FDA Breakthrough Therapy designation for Sovaldi (Sofosbuvir), which was approved by the FDA in December 2013. In addition, it was given a Notice of Compliance by Health Canada in December 2013, and granted Marketing Authorization by the European Commission in January 2014. Treatment is leading to higher cure rates and shortened, simplified therapy regimens for many Hepatitis C patients.
...
Wikipedia